This is all well and fine njbugatti but consider the institutions that can't buy our MDXG because of all this legal "noise"
We will need these institutions to help drive PPS and smoke the shorts. It's nice we all have low basis shares but are you buying more? Are you helping to put dollars into this "opportunity?"
I bet if we didn't have all this #$%$" going on, our largest shareholder would have started meaningful coverage on MDXG.
Too bad we have to find this on message boards and the top headline on the news wire is FRAUD ALERT
Thank you fox for working to inform shareholders.
I'd like to know what the current MDXG - MDT relationship is looking like now, other than management saying "we are just getting started"
I for one think MDXG has yet to make an impact on MDT and it's team other than Petit knowing the former CEO
As a long time shareholder in MDXG it seems as though Petit is the only one there that reacts
If it wasn't for him I would not have invested period
this is another timed and coordinated release by the "thugs" management has supposedly found and will expose
this is getting tiring
thank you fox
unfortunate we have to hear things like this on message boards and not from management
Betting Candya@# et al thought we would stay firmly below.
Hope they are ready to pick up that phone when the margin clerk is looking for his krude to meet the margin call on the short
MARIETTA, Ga. , Jan. 12, 2015 /PRNewswire/ -- MiMedx Group, Inc.(MDXG) , the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that the status of the Company's National Account contracts with Group Purchasing Organizations ("GPOs") and Integrated Delivery Networks ("IDNs") represent in excess of 4,000 U.S hospitals under contract for MiMedx(MDXG) allografts.
"GPOs and IDNs have become extremely effective financial and performance improvement partners for healthcare providers," said Parker H. Petit, Chairman and CEO. "These GPOs and IDNs have proven track records for assisting providers in improving patient outcomes and reducing costs and waste. We share these same goals of improving patient outcomes while reducing costs. We are very pleased with the pace at which we have entered into contractual relationships with various GPOs and IDNs, and we attribute that success to our shared philosophy. Our peer-reviewed published clinical studies have shown that the application of our allografts results in high rates of complete wound healing, less time to achieve wound healing, reduced costs and minimal product wastage."
The Company reported that several of the GPO and many of the IDN contracts contain amniotic tissue skin substitute commitment levels for MiMedx(MDXG) allografts.
Bill Taylor , President and COO, commented, "We have assembled a strong National Accounts sales team, and we are in on-going negotiations with many other GPOs and IDNs. Certain of these IDNs are affiliated with the GPOs currently under contract with MiMedx(MDXG), and some have other GPO affiliation. We will continue to focus on the expansion of our network of GPOs and IDNs under contract with MiMedx(MDXG). We are extremely pleased that the majority of our current GPO and IDN contracts provide for the full line of MiMedx(MDXG) products and allografts. With the countless private, community, and specialty hospitals, along with the managed care organizations, physician networks, community health centers, home care, and other health-related providers under contract with these GPOs and IDNs, we are continually increasing the base of patients who have access to and can benefit from our clinically effective and cost effective allografts."
Petit concluded, "We want to be treated the same as other industry participants. Also, as previously stated, our announced 2015 forecast for revenue to range from $175 million to $190 million is not dependent on our ability to continue to market a micronized product. Nor do we expect the Draft Guidance to impact our ability to achieve the forecasted revenues. In addition, I am pleased to advise shareholders that we will exceed the upper end of our revenue guidance for both the 4th quarter and full year 2014. We will provide further details in a press release on January 12, 2014, prior to the J.P. Morgan Healthcare Conference."
This little gem posted on sleezy alpha on Jan 5?
If yes, sorry for being redundant. It's like clock work with these pie holes
MiMedx - A Contrarian Viewpoint
Jan. 5, 2015 11:12 AM ET | About: MiMedx Group Inc. (MDXG)
Subscribers to SA PRO had an early look at this article. Learn more about PRO »
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
•Large product opportunities overstate real-world usage.
•Reimbursement for their flagship product is being lowered for 2015, a trend likely to continue.
•What’s next in the pipeline? Previous products have disappeared and the injectable product was withdrawn.
•Too much love? Robust valuation means that any slow-down in growth or inability to maintain product momentum WILL have serious effects.
•Regulatory action on withdrawal of injectable product and now a subpoena on sales and marketing practices. Fool me twice.
MiMedx (NASDAQ:MDXG) is the self-acclaimed global leader, processor, marketer, and distributor of human amniotic tissue. Revenue growth and the promise of imminent profitability has propelled this previously little-known start-up into the leagues of a billion dollar market cap healthcare company. The VAST majority of this growth has occurred subsequent to the MiMedx acquisition of Surgical Biologics for $7 Million in 2010. In hindsight this acquisition transformed MiMedx from a struggling developer of hydrogel and collagen technology platforms into a strong amniotic tissue player. Recent commentary and run-up in the stock demands a critical eye on the history of this company and rationale behind this appreciation.
how _ bout, from your post just submitted I think the questions you outline are worth stating again.
We have a VERY confident management team. Lets hear it Pete and Bill! Don't be conservative while others throw grenades at this company and it's shareholders!
Time to call out these cockroaches and get our story out. An upgrade from JPM would be nice as well ; )
agree the idea they could reformulate the injectable in order to make it less than minimally manipulated seems fanciful to a layman, since the very loss of tensile strength and sheet form seems to be what the FDA is all bugged up about.....and it's also very interesting that they claim this interpretation of more than minimally manipulated is very much a new interpretation from the FDA... that seems strange also, and would be nice to hear what MDXG's understanding of the previous standard was........and finally, they say they want fair treatment, that there are at least nine other companies out there with products that are more than minimally manipulated under these standards, who have not received any letters...... who and what products??? A lot of unknowns in the mix here.....will indeed be interesting on Monday
2 days ago the drop was due to unknows around pricing and now that they have increased this removes the issue of dilution.
Today it's the real pure and simple
This is the cheapest energy company (next to Gazprom) on the planet in terms of future earnings.
Buying hand over fist at this level
Any thoughts regarding the following and it's relation to "minimally manipulated?"
The Food and Drug Administration has released new guidance for the use of products for cellular therapy.
The new regulations are contained in Section 1271.15b of CFR21, titled “Human Cells, Tissues, and Cellular and Tissue-Based Products,” known as HCT/Ps. The stated purpose is to establish practices and eligibility and prevent spread of diseases. The section requires providers to register with the FDA Center of Biologics Evaluation and Research and comply with regulations. Section 1271 gives several exceptions for products that are considered to have minimal changes to the cells or pose minimal risk.
The exceptions to the regulations include: 1) autologous use, in which the HCT/P is removed and implanted back to the same individual; 2) implanting the HCT/P back to the “same individual within the same surgical procedure”; 3) the HCT/P cells have been “minimally manipulated” and remain in their “original form”; and 4) the risk of disease transmission is no different from surgical procedures.
Centrifugation is not specifically mentioned in the document. This point may be clarified in the final guidance, but until it is clarified, we are assuming it is permitted under the minimal manipulation rule. If centrifugation is not permitted, additional therapies would be required to register, and this would put pressure on “do it yourself” operators.
We see the new guidelines as a positive as regulators move to define what is manipulated and requires clinical trials through either device or biologic pathways.
Cytori’s (ticker: CYTX ) adipose-derived stem and regenerative cells ( ADRC ) are made from cells that are taken from adipose tissue and then extracted through a process of washing, enzymatic digestion, and filtration. According to Section 1271, the “combination with another article” and use of collagenase would mean that ADRC requires registration with the FDA. As such, we believe Cytori will need to purse a biologics license application (BLA) pathway for product indications.
Cesca Therapeutics (KOOL) has bioprocess technologies that are used for both therapeutic development (SurgWerks) and biobanking (MarrowXpress System). These systems isolate and concentrate different types of bone marrow cells. This process does not use cell separation media or agents to fractionate the cells. This retains cells in their original form and would fit the definition of “minimally manipulated.” As such, we believe Cesca may pursue therapeutic approvals through a device pathway.
IntelliCell BioSciences ( SVFC ) has developed an autologous product called stromal vascular fraction cells. This technology uses ultrasound, rather than enzymes or agents, to separate vascular cells from a sample of adipose tissue. It then transplants them back to the donor. This process seems to fit the definitions of “autologous” and “minimally manipulated.”